fluorodeoxyglucose f18 has been researched along with cabazitaxel in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bijnsdorp, IV; Geldof, AA; Hoekstra, OS; Oprea-Lager, DE; van de Ven, PM; van den Eertwegh, AJ; van Kanten, MP; van Moorselaar, RJ | 1 |
| Azad, AA; Buteau, JP; Davis, ID; Emmett, L; Francis, RJ; Hofman, MS; Iravani, A; Joshua, AM; Lee, ST; Martin, AJ; McJannett, MM; Sandhu, S; Scott, AM; Stockler, MR; Williams, SG; Zhang, AY | 1 |
1 trial(s) available for fluorodeoxyglucose f18 and cabazitaxel
| Article | Year |
|---|---|
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
Topics: Adolescent; Adult; Australia; Fluorodeoxyglucose F18; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
1 other study(ies) available for fluorodeoxyglucose f18 and cabazitaxel
| Article | Year |
|---|---|
[18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Choline; Docetaxel; Drug Screening Assays, Antitumor; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Inhibitory Concentration 50; Male; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Rhodamines; Taxoids | 2015 |